SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Pictured: Novartis Building/iStock, JHVE Photo
Drug Development
Novartis Scores Phase III Chronic Hives Wins as Sanofi Challenges
Late-stage data from two studies showed Novartis’ BTK inhibitor remibrutinib improves symptoms of chronic spontaneous urticaria. The company will file for regulatory approval in 2024.
August 9, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Eli Lilly Campus in San Diego
Business
Lilly Beats Q2 Estimates, Increases Revenue Forecast on Strong Mounjaro Demand
Eli Lilly reported second-quarter revenue of over $8.3 billion, a 28% increase versus Q2 2022, beating estimates of $7.58 billion. The company Tuesday raised its full-year guidance by $2.2 billion.
August 8, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Gilead's headquarters in Silicon Valley/
Business
Gilead’s Strong Q2 Sales Offset by Legal Settlement, COVID Cliff
Thursday, Gilead Sciences reported lower second-quarter profit due to a drop in sales of the company’s Veklury antiviral and a $525 million legal settlement, while slightly raising its sales outlook for the year.
August 4, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Facade of Moderna's building in Massachusetts
Business
Moderna Raises COVID-19 Vaccine Forecast Amid Sharp Drop in Q2 Revenue  
The biotech Thursday reported that second-quarter sales of its COVID shot dropped 94%. However, it expects $6 billion to $8 billion in revenue this year, up from a previous forecast of $5 billion.
August 3, 2023
 · 
3 min read
 · 
Kate Goodwin
Pictured: Businessmen shaking hands/iStock, AmnajK
Business
Illumina, Guardant Dismiss Litigation and Extend Commercial Relationship
Following a year-long legal battle, Illumina is dropping the intellectual property allegations against Guardant. The companies have also entered into a new long-term purchase and supply commitment.
August 2, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Pfizer office in Brussels, Belgium/iStoc
Business
Pfizer Misses on Q2 Revenue as COVID-19 Sales Tank, Narrows 2023 Forecast
In its second-quarter earnings reported Tuesday, Pfizer announced total revenues declined 54% to $12.7 billion, primarily due to a plummet in Paxlovid and Comirnaty sales.
August 1, 2023
 · 
3 min read
 · 
Kate Goodwin
Pictured: Woman in mental anguish/iStock, Marina D
Drug Development
Sumitomo, Otsuka’s Schizophrenia Candidate Fails Phase III Trials
Ulotaront failed to meet primary endpoints in two studies. The companies said high COVID-19 placebo effect “may have masked molecule’s therapeutic effect” and plan to discuss next steps with the FDA.
July 31, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: AstraZeneca building in Gothenburg/iStoc
Business
AstraZeneca, Pfizer Ink Potential $1B Gene Therapy Deal
The British drugmaker’s rare disease subsidiary Alexion will take on a number of Pfizer’s preclinical gene therapy programs and technologies to advance its genomic medicines pipeline.
July 28, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Bristol Myers Squibb office in California
Business
BMS Reports Q2 Sales Miss Amid Generic Competition, Lowers Full-Year Guidance
Revenue for 2023 is now expected to decline to the low single digits instead of the 2% growth projected. Leadership pointed to the company’s multiple myeloma drugs as the main drags on earnings.
July 27, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Needle drawing up mRNA vaccine/iStock, D
Drug Development
Merck, Moderna Launch Pivotal Cancer Vaccine Trial for High-Risk Melanoma
The Phase III trial, which will test the companies’ mRNA-based personalized cancer vaccine and Merck’s blockbuster Keytruda checkpoint inhibitor, is slated for completion by the fall of 2029.
July 26, 2023
 · 
2 min read
 · 
Kate Goodwin
John Tlumacki/The Boston Globe via Getty Images
Business
Biogen to Cut 1,000 Jobs as Part of $1B Cost Savings Plan
The biotech’s “Fit for Growth” program, which includes the headcount reduction, is expected to generate a net savings of $700 million on operating expenses by 2025.
July 25, 2023
 · 
3 min read
 · 
Kate Goodwin
Pictured: Respiratory syncytial virus vial and syr
Drug Development
Bavarian Nordic Drops Out of RSV Vaccine Race with Phase III Flop
The Danish vaccine maker’s respiratory syncytial virus candidate did not meet all primary endpoints in a late-stage study in older adults and the company is discontinuing the program.
July 24, 2023
 · 
2 min read
 · 
Kate Goodwin
Courtesy of Daiichi Sankyo
FDA
Daiichi Sankyo’s FLT3 Inhibitor Gets FDA Nod as First-Line AML Treatment
After being rejected by an FDA advisory panel four years ago, Vanflyta is now approved across three phases of treatment for acute myeloid leukemia patients with the FLT3 gene mutation.
July 21, 2023
 · 
2 min read
 · 
Kate Goodwin
Courtesy of Michael Vi/Getty Images
Business
J&J Exceeds Q2 Expectations, Oncology and Immunology Top Pharma Drivers
The company’s sales guidance for 2023 has been raised to $98.8 billion to $99.8 billion, driven by cancer drugs and medical devices. J&J’s stock rose about 5% in early trading Thursday.
July 20, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: A silhouette of a woman sitting on the f
Drug Development
Neumora Races Toward Phase III with New Driver in the Hot Seat
Less than two years after launch, the startup posts positive Phase II results and heads into Phase III trials for major depressive disorder with a new CEO.
July 18, 2023
 · 
2 min read
 · 
Kate Goodwin
Load More